
    
      The present study was an observational, multicenter, non-interventional, single arm, open
      label, PMS study conducted in Iran.

      Data was gathered in two booklets, each containing information on four cycles of
      chemotherapy, which was filled by the designated physician. The duration of PegaGenÂ®
      treatment was at the physicians' discretion based on the patient's condition.

      The primary objective of this study was safety assessment, including the rate of AEs. The
      secondary objective was the effectiveness evaluation in the prevention of
      chemotherapy-induced FN.

      This study was single arm and 654 subjects participated across various tumor types and
      regimens.
    
  